Eftilagimod alfa is under clinical development by Immutep and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Eftilagimod alfa’s likelihood of approval (LoA) and phase transition for Non-Small Cell Lung Cancer took place on 10 Oct 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Eftilagimod alfa Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Eftilagimod alfa overview

eftilagimod alfa (IMP-321, EDP-202) is under development for the treatment of HER2-negative hormone receptor-positive metastatic breast cancer, soft tissue sarcoma, peritoneal cancer, triple-negative breast cancer, non-small cell lung cancer, recurrent head and neck cancer squamous cell carcinoma, as an adjuvant therapy for metastatic melanoma, hepatocellular carcinoma and solid tumors. It is administered through subcutaneous, intratumoral and intraperitoneal routes. It is a recombinant soluble human lymphocyte-activation gene 3 (LAG-3) IgG Fc fusion protein. The drug candidate is developed by using ImmuFact technology.

The drug candidate was also under development for hepatitis B, pancreatic adenocarcinoma, unspecified influenza virus infection, metastatic renal cell carcinoma, coronavirus disease 2019 and prostate cancer.

Immutep overview

Immutep is a developer of immunotherapeutic products for the treatment of cancer and autoimmune diseases. The company provides products based on the LAG-3 immune control mechanism which is active in the regulation of the T cell immune response. It develops IMP761, a humanized monoclonal antibody that binds to LAG-3 and autoreactive T-cells as an agonist to reduce immune reactions in autoimmune diseases, and others. Immutep’s IMP321 is in clinical development for the treatment of a range of cancer indications. The company collaborates with pharmaceutical and biotech companies for research and development activities. It has operations in Australia, Germany and France. Immutep is headquartered in Sydney, New South Wales, Australia.

Quick View Eftilagimod alfa LOA Data

Report Segments
  • Innovator
Drug Name
  • Eftilagimod alfa
Administration Pathway
  • Intraperitoneal
  • Intratumor
  • Subcutaneous
Therapeutic Areas
  • Infectious Disease
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.